ArticleThe Journal of dermatology2025

Efficacy and Safety of the Topical Gene Therapy Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Study of Japanese Subjects With Dystrophic Epidermolysis Bullosa.

Ken Natsuga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.